Fusobacterium necrophorum sepsis after tonsillitis/pharyngitis

BMJ Case Rep. 2019 Jan 29;12(1):e222287. doi: 10.1136/bcr-2017-222287.

Abstract

Fusobacterium necrophorum is a rare infection most notable for causing Lemierre's syndrome. This consists of a primary oropharyngeal infection and septic thrombophlebitis, and one or more metastatic focus. Prior to the widespread use of antibiotics, Lemierre's syndrome commonly followed a rapidly progressing course, with a high mortality. We describe a case of a previously well 18-month-old boy who presented to the emergency department with a 3-week history of progressive, right-sided, painful neck swelling and systemic sepsis. He was initially treated conservatively with intravenous antibiotics, but ultimately required surgical drainage. Lemierre's syndrome is a rare condition with increasing incidence which can have significant adverse outcomes including death. Early recognition and treatment are essential, but identifying Lemierre's disease is challenging.

Keywords: emergency medicine; exposures; general practice / family medicine; infectious diseases; otolaryngology / ent.

Publication types

  • Case Reports

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Cranial Sinuses / diagnostic imaging
  • Cranial Sinuses / microbiology
  • Diagnosis, Differential
  • Drainage
  • Fusobacterium necrophorum / isolation & purification*
  • Humans
  • Infant
  • Jugular Veins / diagnostic imaging
  • Jugular Veins / microbiology
  • Lemierre Syndrome / complications*
  • Lemierre Syndrome / diagnosis*
  • Lemierre Syndrome / drug therapy
  • Male
  • Neck / diagnostic imaging
  • Neck / microbiology
  • Pharyngitis / complications*
  • Pharyngitis / drug therapy*
  • Radiography, Interventional
  • Sepsis / complications*
  • Sepsis / diagnosis
  • Sepsis / drug therapy
  • Tomography, X-Ray Computed
  • Tonsillitis / complications
  • Tonsillitis / drug therapy
  • Treatment Outcome
  • Ultrasonography

Substances

  • Anti-Bacterial Agents
  • Amoxicillin-Potassium Clavulanate Combination